Skip to content

Inspection prep notes · Supply, manufacturing and packaging

Process validation

Also called: process performance qualification, PPQ

FDA looks less at whether a process validation document exists than at whether the products and process conditions in use today are supported by that validation. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Process validation was not performed for products being manufactured

During the inspection, you stated that you had not performed process validation for (b)(4) of the (b)(4) drug products you manufacture on Unit (b)(4) lines.

FDA Warning Letter · Dabur India Limited · 2026-08-04 · View document

Specifically, your firm failed to perform an adequate process validation for new products to ensure that the manufacturing process is in a state of control.

FDA 483 · Eosera, Inc. · 2026-07-10 · View document

2Critical process parameters were not adequately established in the validation

The process validation reports provided during the inspection lacked sufficient detail, such as a complete list of the equipment used, the establishment of appropriate critical process parameters, adequate sampling instructions, and acceptance criteria.

FDA Warning Letter · BEO Pharma Inc. dba BEO Pharmaceuticals Inc. · 2025-04-29 · View document

The validation program has not adequately defined critical process parameters and critical quality attributes.

FDA 483 · VitaCare Labs Inc. · 2026-10-23 · View document

3The process was not validated again after a process or batch size change

You did not revalidate your manufacturing processes after making major process changes, nor did you fully execute validation protocols through the completion of all batches.

FDA Warning Letter · Bentley Laboratories LLC · 2026-09-29 · View document

For example, you increased the commercial production batch size and released drug product without appropriate validation.

FDA Warning Letter · Advanced Pharmaceutical Technology · 2025-03-18 · View document

4Hold times were not shown to have no effect on quality

You had no data to demonstrate that your hold time did not adversely affect the quality of your drugs, including bioburden of the bulk formulation.

FDA Warning Letter · Laboratoire Druide Inc. · 2025-06-10 · View document

You have not adequately validated your hold time process to demonstrate you can effectively store in-process USP grade bulk drug products for the established [redacted] day time period.

FDA 483 · PQ Pharmacy LLC · 2026-09-22 · View document

5Validation was not repeated after failing results in the validation

Your firm launched an investigation, IR-2023-036 (dated 09/06/2023) and it was concluded that the rinsing time needed to be increased and the process validation was to be repeated. It appears from your response and the documents provided, the process validation was never repeated.

FDA Warning Letter · Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals · 2025-03-11 · View document

Your firm changed specifications to accommodate the failing process validation batch without investigating why the process cannot meet specifications, modifying the process, or repeating validation with successful batches.

FDA 483 · The Mentholatum Company · 2026-10-22 · View document

Questions to check against your procedures

  1. Is there a process validation for every product and line you manufacture? Has validation been completed for new products?
  2. Do validation reports state the equipment used, critical process parameters, sampling instructions and acceptance criteria?
  3. Are critical process parameters and critical quality attributes defined in the validation program?
  4. Did you revalidate after major process changes or batch size changes? Were all protocol batches fully executed?
  5. Do you have data showing that hold times for bulk and in-process product do not affect quality?
  6. When a validation batch failed, did you investigate the cause and repeat validation? Were specifications changed to accept it?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-16.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.